Friday, December 20, 2019

Xencor Adds To Board

Monrovia-based biopharmaceuticals developer Xencor announced on Friday morning that it has naed a new member of its board of directors. According to the company, it has appointed Dagmar Rosa-Bjorkeson, the former Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals to its board. Rosa-Bjorkeson also previously served at Baxalta, and also had served at Novartis for 17 years, serving is such roles as Vice President and Head of its multiple sclerosis business unit; Vice President, Business Development and Licensing, U.S.; Vice President, respiratory, U.S.; and Country Head and President for Novartis Sweden. Xencor is developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases.